RAD18 is one of the critical molecules responsible for the resistance to chemotherapy and radiotherapy in various cancers (Xie et al, 2014; Wu et al, 2019; Li et al, 2022; Du et al, 2022), therefore, targeting the RING-SAP interface provides a unique way to inhibit RAD18 and could be employed in combination with the genotoxicity-inducing chemo/radio therapies. This evidence concerns the gene RAD18 and cancer.